Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5419831 | 1.00 | CHRNB2 (0.46) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL69462 | 1.00 | CHRNB2 (0.46) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Hydrochloric Acid SCHEMBL8825031 | 0.98 | CHRNB2 (0.44) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Hydrochloric Acid SCHEMBL8825028 | 0.98 | CHRNB2 (0.44) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Acetic Acid SCHEMBL31187079 | 0.94 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL5419834 | 0.89 | CYP1A2 (0.47) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL9439033 | 0.89 | CYP1A2 (0.47) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL8825055 | 0.89 | CYP1A2 (0.47) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL8825045 | 0.89 | CYP1A2 (0.47) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL406772 | 0.89 | CYP1A2 (0.47) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3240542-B1 | BTK INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-11-06 | — | — | EP | disclosed |
| US-10130630-B2 | BTK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-11-20 | — | — | US | disclosed |
| US-20170340631-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-11-30 | — | — | US | disclosed |
| EP-0646116-B1 | PROCESS AND INTERMEDIATES FOR BIS-AZA-BICYCLIC ANXIOLYTIC AGENTS | PFIZER (US) | 1999-10-13 | — | — | EP | disclosed |
| US-5719286-A | Process and intermediates for bis-aza-bicyclic anxiolytic agents | PFIZER INC. (US) | 1998-02-17 | — | — | US | disclosed |
| US-5637713-A | REACTING CIS CONFIGURATION WITH AN ALDEHYDE IN FORMIC OR ACETIC ACID | PFIZER INC. (US) | 1997-06-10 | — | — | US | disclosed |
| EP-0586376-B1 | Process and intermediates for the preparation of anxiolytic perhydro-1H-pyrido[1,2-a]pyrazines | PFIZER (US) | 1997-05-28 | — | — | EP | disclosed |
| EP-0607163-B1 | NEUROLEPTIC 2-SUBSTITUTED PERHYDRO-1-H-PYRIDO[1,2-a]PYRAZINES | PFIZER (US) | 1996-12-11 | — | — | EP | disclosed |
| US-5565453-A | Neuroleptic 2-substituted perhydro-1-h-pyrido[1,2-a]pyrazines | PFIZER INC. (US) | 1996-10-15 | — | — | US | disclosed |
| US-5489688-A | INTERMEDIATES FOR ANTIPSYCHOTICS | PFIZER INC. (US) | 1996-02-06 | — | — | US | disclosed |
| US-5326874-A | Intermediate for neuroleptic pyrido(1,2-a)pyrazines | PFIZER INC. (US) | 1994-07-05 | — | — | US | disclosed |
| EP-0586376-A1 | PROCESS AND INTERMEDIATE FOR CERTAIN BIS-AZA-BICYCLIC ANXIOLYTIC AGENTS. | PFIZER (US) | 1994-03-16 | — | — | EP | disclosed |
| WO-1993025552-A1 | PROCESS AND INTERMEDIATES FOR BIS-AZA-BICYCLIC ANXIOLYTIC AGENTS | PFIZER INC. (US) | 1993-12-23 | — | — | WO | disclosed |
| EP-0573467-A1 | NEUROLEPTIC PERHYDRO-1H-PYRIDO 1,2-a]PYRAZINES. | PFIZER (US) | 1993-12-15 | — | — | EP | disclosed |
| EP-0573464-A1 | PROCESS FOR PREPARING TRANS-PIPERIDINE-2,5-DICARBOXYLATES. | PFIZER (US) | 1993-12-15 | — | — | EP | disclosed |
| US-5185449-A | PROCESS AND INTERMEDIATE FOR CERTAIN BIS-AZA-BICYCLIC ANXIOLYTIC AGENTS | PFIZER INC. (US) | 1993-02-09 | — | — | US | disclosed |
| US-5157034-A | Neuroleptic perhydro-1H-pyrido[1,2-a]pyrazines | PFIZER INC. (US) | 1992-10-20 | — | — | US | disclosed |
| WO-1992015575-A1 | PROCESS AND INTERMEDIATE FOR CERTAIN BIS-AZA-BICYCLIC ANXIOLYTIC AGENTS | PFIZER INC. (US) | 1992-09-17 | — | — | WO | disclosed |
| WO-1992015561-A2 | PROCESS FOR PREPARING TRANS-PIPERIDINE-2,5-DICARBOXYLATES | PFIZER INC. (US) | 1992-09-17 | — | — | WO | disclosed |
| WO-1992015580-A1 | NEUROLEPTIC PERHYDRO-1H-PYRIDO[1,2-a]PYRAZINES | PFIZER INC. (US) | 1992-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10130630-B2 | BTK inhibitors | BTK, SYK, LYN | CHRNB2 4687/4885CHRNA4 4842/4885CHRNB4 4748/4885 |
| US-20170340631-A1 | BTK INHIBITORS | BTK, SYK, LYN | CHRNB2 4687/4885CHRNA4 4842/4885CHRNB4 4748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.